WASHINGTON — President Donald Trump on Thursday celebrated the completion of 17 drug pricing agreements, including the final deal with Regeneron, fulfilling a key White House initiative launched last year.
Under the private agreement, Regeneron will reduce prices on drugs for Medicaid, offer its cholesterol medication Praluent at $225 through the TrumpRx program, and invest $27 billion in drug development in the United States.
On the same day, Regeneron announced that the U.S. Food and Drug Administration (FDA) had approved Otarmeni, the first gene therapy to receive clearance under the agency’s new National Priority Voucher program.
In early clinical trials, Otarmeni demonstrated modest hearing improvements for individuals with a rare form of hearing loss. However, the drug’s development has faced opposition from segments of the Deaf community.
Regeneron has committed to providing Otarmeni at no cost to American patients.
Related articles
Optimal Sleep Duration May Slow Biological Aging, Study Finds
Recent research has found an association between sleep duration and biological aging. Image Credit: ArtistGNDphotography/Getty Images A recent study f...
Trump Backs Julia Letlow Against Bill Cassidy in Louisiana GOP Primary
NEW ORLEANS — U.S. Sen. Bill Cassidy is fighting for his political life in Louisiana’s Republican primary on Saturday as he faces a challenge backed b...
Do 'Blue Zones' Really Prove Longevity? Experts Weigh the Science
Below is a lightly edited, AI-generated transcript of the “First Opinion Podcast” interview with Shelley Wood and Eric Topol. Be sure to sign up for t...
Marty Makary's FDA Resignation Highlights Agency Turmoil Amid Leadership Shifts
On Tuesday, Food and Drug Administration Commissioner Marty Makary resigned from his position, leaving a vacancy at the top of the agency to match the...
Health Policy Experts Analyze Vaccines, Vaping, Drug Costs, and TrumpRx on Major Networks
KFF Health News chief Washington correspondent Julie Rovner discussed federal policy on vaccine research, vaping, and drug access on Science Friday on...
FDA Drug Center Acting Director Tracy Beth Høeg Departs Amid Leadership Changes
WASHINGTON — The acting director of the Food and Drug Administration’s drug center, Tracy Beth Høeg, is leaving the agency, according to three sources...
Robert F. Kennedy Jr. Balances Vaccine Skepticism with Ohio Outreach Tour
Here in Washington, we’ve been hearing about tensions between the White House and one of its most controversial — but, at least in some circles, most...
Takeda to Pay $13.6M for Alleged Kickbacks to Doctors Prescribing Antidepressant
Takeda Pharmaceuticals agreed to pay $13.6 million to settle allegations that it paid kickbacks to doctors to prescribe an antidepressant and, consequ...